# Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI

> **NCT00546260** · PHASE2 · TERMINATED · sponsor: **Portola Pharmaceuticals** · enrollment: 70 (actual)

## Conditions studied

- Myocardial Infarction

## Interventions

- **DRUG:** placebo
- **DRUG:** PRT060128 Potassium

## Key facts

- **NCT ID:** NCT00546260
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** Administrative reasons.
- **Last updated:** 2023-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00546260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00546260, "Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00546260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*